Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263196 | 1.00 | TSHR (0.33) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL7620117 | 1.00 | TSHR (0.33) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL1424739 | 0.86 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1783555 | 0.86 | ALDH1A1 (0.37) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL7942903 | 0.86 | ALDH1A1 (0.37) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL10582699 | 0.85 | THRB (0.42) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL10582693 | 0.85 | THRB (0.48) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL6263167 | 0.85 | THRB (0.48) | TSHRTHRBBLMPMP22NPSR1 | |
| SCHEMBL14781080 | 0.83 | — | — | |
| SCHEMBL17279084 | 0.82 | ALDH1A1 (0.40) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117636-B1 | METHOD FOR PREPARING TRION-BIS(OXIME ETHER) DERIVATIVES ANDRION-MONO AND TRION-BIS(OXIME ETHER) DERIVATIVES OBTAINED THEREWITH | BASF AG (DE) | 2002-12-11 | — | — | EP | claimed |
| US-6441236-B1 | HYDROLYSIS, AMINATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-27 | — | — | US | claimed |
| EP-1296939-B1 | METHOD FOR THE PRODUCTION OF TRIOXIME DERIVATIVES | BASF AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-6906223-B2 | Method for the production of trioxime derivatives | BASF AG (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20030163002-A1 | Method for the production of trioxime derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-28 | — | — | US | disclosed |
| US-6441236-B1 | HYDROLYSIS, AMINATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030163002-A1 | Method for the production of trioxime derivatives | CBR3, TDO2, CBR1 | TSHR 1871/4885THRB 883/4885BLM 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.